Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Fine study of GSK3228836 in chronic hepatitis B
NL-OMON52581Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bepirovirsen in Chronic Hepatitis B (CHB), sponsored by GSK. Primary endpoint: Serum HBsAg response after 12 weeks. Started Apr 2021; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON52581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52581.